A Comparison of Radical Prostatectomy and Precision Prostatectomy in Low- and Intermediate-risk Prostate Cancers.

Prostate cancer (PCa) management for low- and intermediate-risk patients often involves radical prostatectomy (RP), which achieves oncologic control but is associated with significant functional impairments, such as erectile dysfunction (50-70%) and urinary incontinence (5-20%). To address these issues, precision prostatectomy (PP) has emerged as a novel surgical approach that preserves functional structures while removing \>90% of prostate tissue. PP is thought to provide superior functional outcomes with acceptable oncological control by preserving the capsule, seminal vesicle (SV), and the

Trial Details

NCT ID
NCT07348367
Phase
NA
Sponsor
Henry Ford Health System
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Radical Prostatectomy
  • Precision Prostatectomy
Locations (sample)
  • Detroit, Michigan, United States|42.33143,-83.04575

Key Eligibility Criteria

  • Prostate cancer patients receiving treatment at Henry Ford Health from the investigator or co-investigator who opt for surgery.
  • Prostate-specific antigen (PSA) ≤20 ng/mL
  • Clinical stage ≤cT2
  • Dominant unilateral lesion with Gleason ≤4+3 on biopsy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →